Literature DB >> 17301598

Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm.

Dae Kyoung Cho1, Jin-Oh Choi, Sung Hea Kim, Jinoh Choi, Il Rhee, Chang-Seok Ki, Sang-Chol Lee, Hyeon-Cheol Gwon.   

Abstract

BACKGROUND: Ischemia-modified albumin, a new marker of myocardial ischemia, is known to elevate during ischemia induced by percutaneous coronary intervention. It is, however, not known whether ischemia-modified albumin also elevates during transient coronary vasospasm.
METHODS: We evaluated ischemia-modified albumin in patients undergoing intracoronary ergonovine spasm provocation test (n=26). For additional comparison, ischemia-modified albumin was also evaluated in elective percutaneous coronary intervention patients (n=18) and in patients with normal coronary angiography (n=10). Blood samples were taken from the arterial sheath before the procedure, just after procedural completion, or balloon inflation.
RESULTS: Median ischemia-modified albumin level elevated significantly in patients with positive provocation test compared with baseline [n=16, 106.0 (interquartile range 96.5, 115.5) versus 128.5 (114.8, 171.8) U/ml, P<0.001], whereas it did not change in patients with negative provocation test [n=10, 109.5 (103.3, 115.0) versus 113.5 (104.0, 118.3) U/ml, P=0.108]. Ischemia-modified albumin was also higher after percutaneous coronary intervention [113.5 (101.0, 131.5) versus 151.0 (129.3, 231.0) U/ml, P<0.0001] and did not change in patients with normal coronary angiography [108.5 (99.3, 114.0) versus 110.0 (108.0, 114.0) U/ml, P=0.085]. Ischemia-modified albumin elevation higher than 9 U/ml after provocation test could detect the presence of coronary vasospasm, with an area under the receiver operating characteristic curve of 0.975 (95% confidence interval 0.921-1.000), with a sensitivity of 94% and a specificity of 99%. Serum albumin levels were within reference range for all patients and there was no significant relationship between albumin and baseline ischemia-modified albumin or postischemic ischemia-modified albumin.
CONCLUSION: Thus, ischemia-modified albumin may have a role as a biochemical marker for transient myocardial ischemia induced by coronary vasospasm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301598     DOI: 10.1097/MCA.0b013e328010a49f

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  9 in total

1.  The protective effect of tadalafil on IMA (ischemia modified albumin) levels in experimental renal ischemia-reperfusion injury.

Authors:  Akin Soner Amasyali; Abdullah Akkurt; Ercan Kazan; Mustafa Yilmaz; Bulent Erol; Yuksel Yildiz; Haluk Erol
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease.

Authors:  Luiz Carlos Cichota; Rafael Noal Moresco; Marta Maria Medeiros Frescura Duarte; José Edson Paz da Silva
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

3.  Relationship between raised intraocular pressure and ischemia-modified albumin in serum and humor aqueous: a pilot study in rabbits.

Authors:  Arzu Taskiran Comez; Dilek Ulker Cakir; Funda Kirtay Tutunculer; Baran Gencer; Hasan Ali Tufan
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

4.  Estimation of Ischemia Modified Albumin (IMA) Levels in Patients with Acute Coronary Syndrome.

Authors:  Prema Gurumurthy; Sai Krishna Borra; Rama Krishna Reddy Yeruva; Dolice Victor; Sai Babu; K M Cherian
Journal:  Indian J Clin Biochem       Date:  2013-08-10

5.  The evaluation of the oxidative stress parameters in patients with primary angle-closure glaucoma.

Authors:  Dong Chang; Qian Sha; Xuefei Zhang; Peipei Liu; Shengzhong Rong; Tao Han; Ping Liu; Hongzhi Pan
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

Review 6.  Ischemia-Modified Albumin as a Marker of Acute Coronary Syndrome: The Case for Revising the Concept of "N-Terminal Modification" to "Fatty Acid Occupation" of Albumin.

Authors:  Ismail Oran; Bulent Oran
Journal:  Dis Markers       Date:  2017-03-05       Impact factor: 3.434

7.  The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism.

Authors:  Suleyman Turedi; Abdulkadir Gunduz; Ahmet Mentese; Murat Topbas; Suleyman C Karahan; Selman Yeniocak; Ibrahim Turan; Oguz Eroglu; Utku Ucar; Yunus Karaca; Suha Turkmen; Robert M Russell
Journal:  Respir Res       Date:  2008-05-30

8.  Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.

Authors:  Yüksel Çavuşoğlu; Şule Korkmaz; Selda Demirtaş; Erkan Gencer; Hatice Şaşmaz; Fezan Mutlu; Hakan Güneş; Uğur Kadir Mert; Sedat Özdemir; Süleyman Kalaycı; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

Review 9.  Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding.

Authors:  James P C Coverdale; Kondwani G H Katundu; Amélie I S Sobczak; Swati Arya; Claudia A Blindauer; Alan J Stewart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-07-20       Impact factor: 4.006

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.